The effect of L-arginine in non-alcoholic fatty liver

Phase 3

• Conditions: fatty liver.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20230409057859N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 1 May 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with non-alcoholic fatty liver
Patients over 18 years old

Exclusion Criteria

• pregnant women
• Patients with liver cirrhosis
• Patients with viral and autoimmune hepatitis
• Patients with advanced heart and kidney diseases
• Patients with celiac disease
Wilson's patients

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement of hepatic steatosis. Timepoint: before the start of the intervention and 3 months after the intervention. Method of measurement: fibro scan.;Alanine Aminotransferease (ALT) allevation. Timepoint: before the start of the intervention and 3 months after the intervention. Method of measurement: blood test- biochemical marker.;Fibrosis Index -for liver based in 4 factors (Fib-4) alleviation. Timepoint: before the start of the intervention and 3 months after the intervention. Method of measurement: Mathematical formula fib-4.

Secondary Outcome Measures

Name	Time	Method
BMI alleviation. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Height and weight ratio formula.